Analyst Yun Zhong of Wedbush reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report), retaining the price target of $9.00.
Yun Zhong has given his Buy rating due to a combination of factors including Voyager Therapeutics’ recent interactions with the FDA, which have been positive and suggest no anticipated delays in their tau silencing gene therapy program for Alzheimer’s Disease. The company’s management has expressed strong confidence in their ability to develop effective treatments, bolstered by the FDA’s consistent policy and focus on patient-centered innovation.
Additionally, Voyager Therapeutics has a solid financial position, ending the first quarter of 2025 with $295 million in cash, which is expected to support operations into mid-2027. The anticipated tau PET imaging data in the second half of 2026 is also expected to confirm the efficacy of their tau antibody, VY7523, in preventing tau spreading. These factors, along with promising preclinical data from their VY1706 program, contribute to the positive outlook and Buy rating for VYGR shares.
Zhong covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Ascendis Pharma, and Voyager Therapeutics. According to TipRanks, Zhong has an average return of -19.3% and a 32.29% success rate on recommended stocks.
In another report released on May 5, H.C. Wainwright also maintained a Buy rating on the stock with a $30.00 price target.